Benlysta Is Niche, But Growing, So GSK's Not Giving Up On Lupus

Sales of the BLyS inhibitor disappointed at launch, but the franchise is growing double-digits and now a new, more convenient subcutaneous formula will provide another growth opportunity.

Knee joint

GlaxoSmithKline PLClaunched a new subcutaneous formulation of Benlysta (belimumab) in August that could make the drug easier to use for some patients with systemic lupus erythematosus (SLE) than the original intravenous version. The US FDA approved the new formulation, administered as a once-weekly 200mg injection, July 22.

Benlysta probably is best recognized by industry watchers as the blockbuster that never was. GSK and its then-partner Human...

More from Immunological

More from Therapeutic Category